Low-dose vs. standard-dose alteplase for acute ischemic stroke: a real-world single-center retrospective study
The study highlights the complexity of treatment decision-making for intravenous alteplase in AIS, with significant influences from both patient and physician factors. Low-dose alteplase demonstrated similar clinical outcomes to standard-dose alteplase in this real-world setting. Future research should focus on optimizing treatment decisions and improving guideline adherence to enhance patient outcomes.
Authors
- Lina Ge (ORCID: https://orcid.org/0000-0002-6362-5492)
- Shizheng Zhang (ORCID: https://orcid.org/0000-0003-2441-3160)
- Qing-Qing Zhuang
- Yaxi Zhang (ORCID: https://orcid.org/0000-0003-1394-525X)
- Sisi He (ORCID: https://orcid.org/0000-0003-0769-9590)
- Xinxin Chen (ORCID: https://orcid.org/0000-0002-4766-8169)
- Xin-Lei Mao
- Cai-Dan Lin
Institutions
- Wenzhou Medical University (CN)
- Wenzhou Central Hospital (CN)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3389/fneur.2025.1651307
- Primary Topic
- Acute Ischemic Stroke Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Health Commission of the People's Republic of China